Ocugen, Inc.

What they do

Ocugen is developing a modifier gene therapy platform based on nuclear hormone receptors (NHRs), intended as a gene-agnostic approach to retinal diseases. The lead program OCU400 targets retinitis pigmentosa (RP), OCU410ST targets Stargardt disease (ST), and OCU410 targets geographic atrophy (GA) secondary to dry age-related macular degeneration. The company has no commercial products and reported annual revenue of $4.4 million in 2025.

Revenue drivers

• No commercial product revenue — The company had no approved products as of the latest filings; annual revenue was $4.4 million in 2025, $4.1 million in 2024 and $6.0 million in 2023, with recent quarterly revenue of $1.5 million in both Q1 and Q2 2026.
• Potential future product sales — Future revenue depends on approval and commercialization of OCU400 for RP, OCU410ST for Stargardt disease and OCU410 for GA; no product sales have been recorded to date.
• Potential licensing and regional partnerships — In Q2 2026 Ocugen signed a binding term sheet with Roots Pharmaceutical and Al-Dhow International Holding to negotiate an exclusive license for OCU400 in RP across the Middle East and North Africa; no license revenue has been reported.

Recent performance

Second quarter 2026 revenue was $1.5 million, matching the first quarter, while annual revenue declined from $6.0 million in 2023 to $4.1 million in 2024 and $4.4 million in 2025. Net loss was $68.0 million in 2025 after $54.0 million in 2024, and operating cash use was $57.0 million in 2025 versus $42.1 million in 2024. At June 30, 2026, total assets were $124.2 million, total liabilities were $140.8 million, shareholders' equity was negative $16.6 million and cash was $100.1 million. In August 2026 the company closed a $130.0 million convertible senior notes financing and said this extended its cash runway into 2028.

Strategy

Ocugen is prioritizing three late-stage retinal gene therapy programs: OCU400 for RP, OCU410ST for Stargardt disease and OCU410 for GA secondary to dry AMD. It completed enrollment in the Phase 3 liMeliGhT trial of OCU400 (N=140) and in the Phase 2/3 GARDian3 trial of OCU410ST (63 subjects), and plans to initiate a Phase 3 trial of OCU410 in 2026 after FDA clearance. The company is preparing a rolling BLA for OCU400 following topline Phase 3 data expected in Q1 2027, with a BLA for OCU410ST planned mid-2027 and BLA/MAA filings for OCU410 targeted for 2028. It also completed OCU400 Process Performance Qualification batches and is pursuing a MENA license for OCU400.

Risks

• Going-concern and funding need — The 10-K states that recurring losses and negative operating cash flow raise substantial doubt about the ability to continue as a going concern absent significant additional funding, and the company had negative shareholders' equity of $16.6 million at June 30, 2026.
• Clinical and regulatory failure — All value depends on OCU400, OCU410ST and OCU410 succeeding in trials and obtaining approval; the 10-Q notes that under FDA policy Ocugen would need to submit topline Phase 3 data in a pre-BLA meeting before the FDA agrees to a rolling submission schedule.
• Reliance on third parties — The 10-K risk factors cite dependence on contract development and manufacturing organizations, suppliers and other third parties for development and potential commercialization.
• No approved products or commercial revenue — The company has recorded no product sales, and revenue has been modest and declining from $6.0 million in 2023 to $4.4 million in 2025, so any delay in approval would leave it without commercial income.

Outlook

Management expects topline Phase 3 data for OCU400 in the first quarter of 2027 and for OCU410ST in the second quarter of 2027, with a BLA for OCU410ST to follow mid-2027 and BLA/MAA filings for OCU410 targeted for 2028. It states it remains on track to begin a rolling BLA submission for OCU400 in the third quarter of 2026, subject to FDA agreement on the submission schedule after topline data. The company says its $130.0 million convertible notes financing extends its cash runway into 2028.